• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Minerva Neurosciences Inc

    12/29/25 8:29:15 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NERV alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    MINERVA NEUROSCIENCES, INC.

    (Name of Issuer)


    COMMON STOCK

    (Title of Class of Securities)


    603380205

    (CUSIP Number)


    12/22/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    603380205


    1Names of Reporting Persons

    Federated Hermes, Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    PENNSYLVANIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    9,392,275.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    9,392,275.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    9,392,275.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    19.86 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP No.
    603380205


    1Names of Reporting Persons

    Voting Shares Irrevocable Trust
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    PENNSYLVANIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    9,392,275.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    9,392,275.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    9,392,275.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    19.86 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  In accordance with Rule 13d-4 under the Exchange Act, Federated Hermes, Inc.; the Voting Shares Irrevocable Trust; Thomas R. Donahue; Ann C. Donahue; and J. Christopher Donahue declare that this report should not be construed as an admission that any of them is the beneficial owner of the securities held by any of the Managed Funds, and each of Federated Hermes, Inc.; the Voting Shares Irrevocable Trust; Thomas R. Donahue; Ann C. Donahue; and J. Christopher Donahue expressly disclaim beneficial ownership of such securities.


    SCHEDULE 13G

    CUSIP No.
    603380205


    1Names of Reporting Persons

    Thomas R. Donahue
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    9,392,275.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    9,392,275.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    9,392,275.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    19.86 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  In accordance with Rule 13d-4 under the Exchange Act, Federated Hermes, Inc.; the Voting Shares Irrevocable Trust; Thomas R. Donahue; Ann C. Donahue; and J. Christopher Donahue declare that this report should not be construed as an admission that any of them is the beneficial owner of the securities held by any of the Managed Funds, and each of Federated Hermes, Inc.; the Voting Shares Irrevocable Trust; Thomas R. Donahue; Ann C. Donahue; and J. Christopher Donahue expressly disclaim beneficial ownership of such securities.


    SCHEDULE 13G

    CUSIP No.
    603380205


    1Names of Reporting Persons

    Ann C. Donahue
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    9,392,275.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    9,392,275.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    9,392,275.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    19.86 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  In accordance with Rule 13d-4 under the Exchange Act, Federated Hermes, Inc.; the Voting Shares Irrevocable Trust; Thomas R. Donahue; Ann C. Donahue; and J. Christopher Donahue declare that this report should not be construed as an admission that any of them is the beneficial owner of the securities held by any of the Managed Funds, and each of Federated Hermes, Inc.; the Voting Shares Irrevocable Trust; Thomas R. Donahue; Ann C. Donahue; and J. Christopher Donahue expressly disclaim beneficial ownership of such securities.


    SCHEDULE 13G

    CUSIP No.
    603380205


    1Names of Reporting Persons

    J. Christopher Donahue
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    9,392,275.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    9,392,275.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    9,392,275.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    19.86 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  In accordance with Rule 13d-4 under the Exchange Act, Federated Hermes, Inc.; the Voting Shares Irrevocable Trust; Thomas R. Donahue; Ann C. Donahue; and J. Christopher Donahue declare that this report should not be construed as an admission that any of them is the beneficial owner of the securities held by any of the Managed Funds, and each of Federated Hermes, Inc.; the Voting Shares Irrevocable Trust; Thomas R. Donahue; Ann C. Donahue; and J. Christopher Donahue expressly disclaim beneficial ownership of such securities.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    MINERVA NEUROSCIENCES, INC.
    (b)Address of issuer's principal executive offices:

    1500 District Avenue, Burlington, MA 01803
    Item 2. 
    (a)Name of person filing:

    Federated Hermes, Inc.
    (b)Address or principal business office or, if none, residence:

    1001 Liberty Avenue, Pittsburgh, PA 15222-3779
    (c)Citizenship:

    Pennsylvania
    (d)Title of class of securities:

    COMMON STOCK
    (e)CUSIP No.:

    603380205
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    See response to Item 9 on each cover page.
    (b)Percent of class:

    See response to Item 11 on each cover page.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See response to Item 5 on each cover page.

     (ii) Shared power to vote or to direct the vote:

    See response to Item 6 on each cover page.

     (iii) Sole power to dispose or to direct the disposition of:

    See response to Item 7 on each cover page.

     (iv) Shared power to dispose or to direct the disposition of:

    See response to Item 8 on each cover page. The Reporting Persons have previously filed a Schedule 13G with respect to the securities of the Issuer, most recently by the amendment filed on January 18, 2024. Subsequently, on October 28, 2025, the Reporting Persons filed a Schedule 13D with respect to the Issuer's securities following a private placement by the Issuer, in which certain of the Reporting Persons participated by acquiring securities and executing a support agreement providing that, among other things, such Reporting Persons would vote in favor of proposals at the Issuer's stockholder meeting. Following the conclusion of such meeting on December 22, 2025, the Reporting Persons determined that they no longer hold securities of the Issuer with a purpose or effect of changing or influencing control of the Issuer, or in connection with or as a participant in any transaction having that purpose or effect. Accordingly, the Reporting Persons are filing this statement on Schedule 13G pursuant to Rule 13d-1(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), in accordance with Rule 13d-1(h) of the Exchange Act.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    See Exhibit "1" Attached
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Federated Hermes, Inc.
     
    Signature:/s/J. Christopher Donahue
    Name/Title:J. Christopher Donahue, as President of Federated Hermes, Inc.
    Date:12/29/2025
     
    Voting Shares Irrevocable Trust
     
    Signature:/s/Thomas R. Donahue
    Name/Title:Thomas R. Donahue, as Trustee of Voting Shares Irrevocable Trust
    Date:12/29/2025
     
    Signature:/s/Ann C. Donahue
    Name/Title:Ann C. Donahue, as Trustee of Voting Shares Irrevocable Trust
    Date:12/29/2025
     
    Signature:/s/J. Christopher Donahue
    Name/Title:J. Christopher Donahue, as Trustee of Voting Shares Irrevocable Trust
    Date:12/29/2025
     
    Thomas R. Donahue
     
    Signature:/s/Thomas R. Donahue
    Name/Title:Thomas R. Donahue
    Date:12/29/2025
     
    Ann C. Donahue
     
    Signature:/s/Ann C. Donahue
    Name/Title:Ann C. Donahue
    Date:12/29/2025
     
    J. Christopher Donahue
     
    Signature:/s/J. Christopher Donahue
    Name/Title:J. Christopher Donahue
    Date:12/29/2025

    Comments accompanying signature:  SEE EXHIBITS 2 AND 3 ATTACHED Exhibit Information EXHIBIT 1 ITEM 3 CLASSIFICATION OF REPORTING PERSONS EXHIBIT 2 AGREEMENT FOR JOINT FILING OF SCHEDULE 13G EXHIBIT 3 POWER OF ATTORNEY
    Get the next $NERV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NERV

    DatePrice TargetRatingAnalyst
    3/4/2022$10.00 → $5.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $NERV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. reiterated coverage on Minerva Neurosciences with a new price target

    HC Wainwright & Co. reiterated coverage of Minerva Neurosciences with a rating of Buy and set a new price target of $5.00 from $10.00 previously

    3/4/22 6:14:09 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NERV
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Minerva Neurosciences Inc

    SCHEDULE 13G - Minerva Neurosciences, Inc. (0001598646) (Subject)

    2/12/26 9:02:51 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Minerva Neurosciences Inc

    SCHEDULE 13G/A - Minerva Neurosciences, Inc. (0001598646) (Subject)

    2/5/26 2:51:20 PM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Minerva Neurosciences Inc filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Minerva Neurosciences, Inc. (0001598646) (Filer)

    2/3/26 9:00:15 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NERV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026

    BURLINGTON, Mass., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, February 3, 2026 at 10:30 AM ET featuring Gregory Strauss, PhD (Franklin Professor of Psychology, University of Georgia) and Brian Kirkpatrick, MD, MSPH (Peters Professor of Psychiatry, University of Arkansas for Medical Sciences). They will join the company management team to elaborate on the patient burden of the negative symptoms of schizophrenia, the challenges associated with asses

    1/26/26 7:00:00 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company's Board of Directors

    BURLINGTON, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced the appointment of Dr. Inderjit Kaul, Chief Medical Officer of Draig Therapeutics, to the board of directors. Dr. Kaul will also serve as a consultant to the Company for the future clinical development of roluperidone. Last month, the Company announced successfully raising up to $200 million in a private placement to fund a confirmatory Phase 3 trial for roluperidone for the treatment of negative symptoms in patients with schizophrenia, resubmission of it

    11/19/25 8:30:00 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates

    BURLINGTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported business updates and financial results for the third quarter of 2025 ending September 30, 2025. Business Updates  On October 23, 2025, the Company received $80 million in gross proceeds in a private placement, before deducting fees and other expenses. The financing includes an initial upfront funding of $80 million and up to an additional $80 million in gross proceeds if all Tranche A warrants are exercised, subject to the terms and conditions speci

    11/5/25 7:30:00 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NERV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Kupfer David

    4 - Minerva Neurosciences, Inc. (0001598646) (Issuer)

    12/23/25 4:15:22 PM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Laghrissi-Thode Fouzia

    4 - Minerva Neurosciences, Inc. (0001598646) (Issuer)

    12/23/25 4:15:17 PM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by SVP, CFO and Secretary Ahlholm Frederick W

    4 - Minerva Neurosciences, Inc. (0001598646) (Issuer)

    12/23/25 4:15:15 PM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NERV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Minerva Neurosciences Inc

    SC 13G/A - Minerva Neurosciences, Inc. (0001598646) (Subject)

    11/12/24 10:32:12 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Minerva Neurosciences Inc

    SC 13G - Minerva Neurosciences, Inc. (0001598646) (Subject)

    2/9/24 9:28:31 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Minerva Neurosciences Inc (Amendment)

    SC 13G/A - Minerva Neurosciences, Inc. (0001598646) (Subject)

    1/18/24 10:21:16 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NERV
    Leadership Updates

    Live Leadership Updates

    View All

    Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company's Board of Directors

    BURLINGTON, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced the appointment of Dr. Inderjit Kaul, Chief Medical Officer of Draig Therapeutics, to the board of directors. Dr. Kaul will also serve as a consultant to the Company for the future clinical development of roluperidone. Last month, the Company announced successfully raising up to $200 million in a private placement to fund a confirmatory Phase 3 trial for roluperidone for the treatment of negative symptoms in patients with schizophrenia, resubmission of it

    11/19/25 8:30:00 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Minerva Neurosciences Announces Promotion of Geoff Race to President

    Frederick Ahlholm is Named Chief Financial Officer as Company Prepares to Submit a Pre-NDA Meeting Request to FDA WALTHAM, Mass., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that Geoff Race, current Executive Vice President, Chief Financial Officer and Chief Business Officer of Minerva, has been promoted to President. Minerva's Senior Vice President and Chief Accounting Officer, Frederick Ahlholm, has been promoted to Chief Financial Officer. The appointments are effective immediately. These latest leadership

    10/11/21 8:30:00 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Minerva Neurosciences Announces Appointment of Dr. Ramana Kuchibhatla as Senior Vice President and Head of Research & Development

    WALTHAM, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced Dr. Jay Saoud's retirement and transition to an advisory role and Dr. Ramana Kuchibhatla's appointment as Senior Vice President and Head of Research & Development, both effective September 16, 2021. Dr. Kuchibhatla will report directly to Dr. Remy Luthringer, Executive Chairman and Chief Executive Officer of Minerva. "I would like to thank Jay for the invaluable skill and leadership which have enabled Minerva to take roluperidone from early stage cl

    9/8/21 8:30:00 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NERV
    Financials

    Live finance-specific insights

    View All

    Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates

    BURLINGTON, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the first quarter ended March 31, 2023. "The first quarter saw the achievement of a significant milestone for our investigational drug, roluperidone, and for Minerva, as the U.S. Food and Drug Administration (FDA) filed our New Drug Application (NDA) for roluperidone for the treatment of negative symptoms of schizophrenia on April 27, 2023. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of

    5/15/23 7:30:00 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Minerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023

    BURLINGTON, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release first quarter 2023 financial results and business updates on Monday, May 15, 2023. The Company will host a webcast that day at 8:30 a.m. Eastern Time to discuss the results and updates. The live conference call may be accessed here and on the Company's website under Events and Presentations. The archived webcast will be available on the Company's website beginning approximately two hours after the event for 90 days. About Miner

    5/8/23 8:30:00 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Minerva Neurosciences Reports Fiscal Year 2022 Fourth Quarter And Year End Financial Results And Business Updates

    BURLINGTON, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the fourth quarter and year ended December 31, 2022. Corporate Update "In 2022, we had multiple interactions with the FDA regarding the regulatory path forward for our lead compound, roluperidone. After submitting an NDA for roluperidone to the FDA in August, we received a Refuse to File letter (RTF) in the fall, which was upheld following another meeting with the FDA. We remain committed to developing roluperid

    3/8/23 7:30:00 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care